Wednesday, July 8, 2026

pharma · Multiple Myeloma · generalized myasthenia gravis · RNAC

Cartesian Therapeutics

Cartesian Therapeutics clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

7495 New Horizon Way, Frederick, Maryland 21703, US HQ
2016 Founded
89 Employees
Public company Type
RNAC · NYSE Ticker
Company details
Status
Public
HQ
7495 New Horizon Way, Frederick, Maryland 21703, US
Founded
2016
Employees
89
Programs
12
Drugs
4
Patents
4
Intelligence · Clinical Programs

Cartesian Therapeutics projects

4 ClinicalTrials.gov programs sponsored by Cartesian Therapeutics.

Cartesian Therapeutics has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Descartes 30

    Cartesian Therapeutics

    Acute Respiratory Distress Syndrome

    phase 1 mab terminated

    1 trial
  2. Descartes-08

    Cartesian Therapeutics

    Multiple Myeloma

    phase 1 mab terminated

    1 trial
  3. Descartes-15

    Cartesian Therapeutics

    Refractory Multiple Myeloma

    phase 1 small molecule terminated

    1 trial
  4. Descartes-25

    Cartesian Therapeutics

    Multiple Myeloma

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does Cartesian Therapeutics have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.